Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 3/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557502 | 0.82 | REN (0.37) | RENKCNH2DPP4 | |
| SCHEMBL556935 | 0.78 | PROKR1 (0.42) | KCNH2SMN1; SMN2L3MBTL1KDM4ELMNA | |
| SCHEMBL534057 | 0.78 | REN (0.58) | RENKCNH2DPP4 | |
| SCHEMBL534498 | 0.77 | SPR (0.43) | RENKCNH2KDM4EHTT | |
| SCHEMBL535144 | 0.76 | REN (0.74) | RENKCNH2LMNA | |
| SCHEMBL533961 | 0.75 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1KDM4ELMNADPP4 | |
| SCHEMBL557684 | 0.74 | REN (0.61) | RENKCNH2 | |
| SCHEMBL556463 | 0.74 | REN (0.58) | RENKCNH2SMN1; SMN2LMNASLC6A4 | |
| SCHEMBL556618 | 0.73 | REN (0.75) | RENKCNH2 | |
| SCHEMBL23291443 | 0.73 | GRM5 (0.42) | SMN1; SMN2L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885SMN1; SMN2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.